Land: Storbritannien
Sprog: engelsk
Kilde: HMA (Heads of Medicines Agencies)
enrofloxacin 150 mg
Le Vet B.V
QJ01MA90
Tablet
enrofloxacin
Cats, Dogs
2011-03-30
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotab 150 mg tablets for dogs Enrotab Vet. (DK) Enrotab Vet. 150 mg tablets for dogs (SE, NO, FI) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Enrofloxacin 150.0 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet A white to slightly yellow, round, convex snap-tab tablet for oral administration to dogs . The tablet can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Treatment of lower urinary tract infections (associated or not with prostatitis) and upper urinary tract infections caused by Escherichia coli or Proteus mirabilis. Treatment of superficial and deep pyoderma. 4.3 CONTRAINDICATIONS Do not use in young or growing dogs (aged less than 12 months (small breed) or less than 18 months (large breed)) as the product may cause epiphyseal cartilage alterations in growing puppies. Do not use in dogs having seizure disorders, since enrofloxacin may cause CNS stimulation. Do not use in dogs with known hypersensitivity to fluoroquinolones or to any of the excipients of the product. Do not use in case of resistance to quinolones, as there exists almost complete cross resistance to other quinolones and complete cross resistance to other fluoroquinolones. Do not use with tetracyclines, phenicols or m Læs hele dokumentet